Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Modernapharmaceuticalscancer vaccinehealthcare
Open a keyword to see other news on the same topic.
Related news
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Moderna shares fell 4% to $193.62 in morning trading, extending an 18% plunge from the prior session, even though full late-stage data for its personalized melanoma vaccine, given with Merck's Keytruda, came back positive. Compared with Keytruda alone, the combination cut the risk of melanoma recurrence or death, a result near analyst expectations but short of the highest hopes built during a rally that began in August. The vaccine carries far more weight for Moderna, whose approved products are all respiratory vaccines, while for Merck it is an add-on to Keytruda; Merck fell 0.8% to $146 and Pfizer 0.7% to $30.22. The iShares Biotechnology ETF was unchanged at $209.54, suggesting the slide is company-specific. The full data will be presented at a medical conference this weekend.
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Moderna shares plunge after leak of partial cancer vaccine data despite positive results
Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
Related markets
Latest news
- Meta announces plans to raise up to $95 billion for AI buildout
Meta (META) stock slipped 2% on Monday morning after the company said it plans to raise up to $95 billion through equity financing to fund its AI infrastructure buildout. The initial $35 billion raise includes about $22.5 billion of Class A common stock and $12.5 billion of Series A mandatory convertible preferred stock. Chip suppliers Nvidia (NVDA), AMD (AMD) and Broadcom (AVGO) expressed interest in buying up to $5 billion of these shares in aggregate. Meta said the capital will support its core business and emerging AI opportunities, including its family of apps, the AI agent Muse and infrastructure.
- Tech stocks rise after Anthropic IPO filing: AlphaCheck
The tech sector (XLK) gained on Monday after AI developer Anthropic filed to go public. Chip makers Nvidia (NVDA), AMD (AMD) and Broadcom (AVGO) jumped, while Meta (META) declined after the company revealed plans to raise up to 95 billion USD to fund its AI infrastructure build-out. In the first few minutes of trading, Brent crude futures (BZ=F) fell to 110 USD per barrel and WTI (CL=F) dropped to 101 USD ahead of a key Federal Reserve policy meeting this week, with most market participants expecting rates to be held steady. Other stocks drawing reader attention on Yahoo Finance this morning included Nu Holdings (NU), Mercado Libre (MELI) and Nebius (PG).
- BC-Gold Futures
The Associated Press gold futures table, quoted in US dollars per troy ounce for 100-ounce contracts, shows prices as of 10:00 AM Monday, October 26. The Dec 26 contract last traded at 4010.50, up 2.60, while the Aug 27 contract rose 27.60 to 4170.20. Estimated volume was 77,861 contracts, open interest stood at 398,298, and open interest rose by 652.
- Tesla Rises 6% as Barclays Upgrade Cites SpaceX Merger Potential; Lucid Drops 4%, Rivian Slips
Tesla (TSLA) shares rose 6% to $394.72 after Barclays upgraded the stock to Overweight from Equal Weight and set a price target of $450. Analyst Dan Levy cited a potential takeover premium from a possible merger with SpaceX (SPCX), along with an expected return to growth in the automotive business driven by Full Self-Driving adoption and higher exports from the Shanghai factory. CEO Elon Musk confirmed the two companies have formed independent committees to explore a combination but stressed that a deal is not certain. Meanwhile, Lucid Group (LCID) fell 4% to $3.38 and Rivian Automotive (RIVN) slipped 2% to $11.64, as neither company is part of the merger discussion. The Global X Autonomous & Electric Vehicles ETF (DRIV) rose 0.5% and the Invesco QQQ Trust (QQQ) gained 0.7%, both well behind Tesla's move.
- Meta funds their AI build-out, Musk raises $40B in chip debt, and Anthropic's IPO
The 8:30 show, hosted by Julie Hyman, Jake Conely and Pras Subramanian, covers the day's top stories, including Meta's plan to raise as much as $95 billion for its AI build-out, SpaceX (SPCX) raising $40 billion to pay down chip debt, and the bulls' reaction to these moves. Anthropic (ANTH.PVT) has officially filed for an IPO, targeted for mid-November.
- Anthropic Makes IPO Filing Public, Plans Nasdaq Listing Under ‘ANT’
Anthropic has filed for an IPO, planning to list its Class A shares on Nasdaq under the ticker “ANT”, with Goldman Sachs and Morgan Stanley leading 24 underwriters. For the first half of 2026, revenue reached 16.29 billion USD (versus 1.16 billion USD a year earlier), but the company posted a net loss of 80.7 billion USD, mainly due to a 72.4 billion USD charge tied to fair value changes in convertible notes and other instruments. A trust will elect a majority of the board, while an entity owned by its seven co-founders will hold 50.1% of voting power; the filing warns this structure may effectively eliminate Class A holders’ ability to influence key decisions. The company previously raised 65 billion USD in May at a 965 billion USD valuation, and the number of shares and price range have not yet been set.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.